Home MarketXLS
Dashboard MarketXLS
Screener MarketXLS
Options Profit Calculator MarketXLS
Stock Ranks MarketXLS
Spreadsheet Builder MarketXLS
Documentation MarketXLS
Logout MarketXLS

PSTX Stock Forecast, Price Targets, Chart, Dividends & Analysis

Poseida Therapeutics Inc. logo

Poseida Therapeutics Inc.

Sector: Manufacturing   

Industry: Biological Product (except Diagnostic) Manufacturing

2.71
 
USD
  
-0.01
  
(-0.37%)
Previous close: 2.72  Open: 2.75  Bid: 2.67  Ask: 3.07
52 week range    
1.87   
   4.27
Mkt Cap: 270 M  Avg Vol (90 Days): 492,232
Peers   
OTIC / 
OTLC / 
OVAT-CA / 
Last updated: Friday 22nd November 2024

Stock Rankings

39
MarketXLS Rank
60
Value
23
Technical
34
Quality
How are these ranks calculated?
Ad slot not ready
Search for a stock

Metrics

Peers

StockDividendMarket Cap (B)PEPrice ($)

ORTH-CA

OTIC

0.0085

OTLC

OVAT-CA

Financials

PSTX Income Statement

Annual
Invalid dateDec-20Dec-21Dec-22Dec-23
Amortization of intangibles4 M4 M4 M
Basic EPS from continuing operations-3.61-2.01-0.89-1.37
Basic EPS total-3.61-2.01-0.89-1.37
Basic weighted shares outstanding36 M62 M72 M90 M
Depreciation3 M5 M5 M6 M
DepreciationAndAmortization3 M5 M5 M6 M
Diluted EPS total-3.61-2.01-0.89-1.37
Diluted normalized net income/share-0.89-1.37
Diluted weighted shares outstanding36 M62 M72 M90 M
GeneralAndAdministrativeExpense23 M36 M38 M37 M
Gross operating profit31 M130 M65 M
Income before tax-130 M-125 M-63 M-123 M
Income taxes-27000.0-139000.0544000.0107000.0
InterestExpenseNonOperating4 M3 M6 M9 M
MiscOtherSpecialCharges280000.020 M3 M15 M
Net income from total operations-130 M-125 M-64 M-123 M
NetIncomeCommonStockholders-130 M-125 M-64 M-123 M
NetIncomeContinuousOperations-130 M-125 M-64 M-123 M
NetNonOperatingInterestIncomeExpense-4 M-3 M-6 M-9 M
Normalized income-125 M-97 M
Operating income-127 M-141 M-60 M-130 M
Operating income before depreciation (EBITDA)-124 M-117 M-52 M-109 M
OperatingExpense127 M173 M190 M194 M
Other income net-280000.0-20 M-3 M15 M
OtherGandA23 M36 M38 M37 M
OtherOperatingExpenses-3 M-4 M-2 M-3 M
Research & development expense104 M137 M153 M157 M
ResearchExpense104 M137 M153 M157 M
Revenue per share4 M4 M4 M
Selling Gen & administrative expense23 M36 M38 M37 M
Total Income available for interest expense (EBIT)-126 M-122 M-57 M-115 M
Total common shares outstanding62 M63 M87 M96 M
Total net income-130 M-125 M-64 M-123 M
Total ordinary shares97 M97 M97 M97 M
Total revenues31 M130 M65 M
TotalExpenses127 M173 M190 M194 M
TotalRevenue31 M130 M65 M
Call: 1-877-778-8358
Ankur Mohan MarketXLS
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.

I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement “your own” investment strategies in Excel with thousands of MarketXLS functions and templates.

MarketXLS is a complete Excel stock solution

Kevin Hsu

StockKevin.com

I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel

Lloyd Lenase

Option Day Trader

MarketXLS is a data junkie’s dream. It gives me the flexibility to mine for hidden treasures.

Dave

Swing trader since 2011

I like to access historical closing prices on a particular date. That makes tracking performance easy.

Patrick Cusatis, Ph.D., CFA

Associate Professor of Finance - Penn State University